NeoTX Therapeutics Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neotx.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- NeoTX Therapeutics Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT04880863
- Locations
- 🇺🇸
NeoTX - 10307, Daphne, Alabama, United States
🇺🇸NeoTX - 10302, Scottsdale, Arizona, United States
🇺🇸NeoTX - 10303, Tucson, Arizona, United States
Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
Phase 1
Recruiting
- Conditions
- ER+ Breast CancerOvarian CancerCervical Squamous Cell CarcinomaPancreatic AdenocarcinomaEndometrial CancerRenal Cell CarcinomaUrothelial CancerHead and Neck Squamous Cell CarcinomaMesotheliomaMelanoma
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- NeoTX Therapeutics Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03983954
- Locations
- 🇮🇳
Shalby Hospital, Ahmedabad, Gujarat, India
🇮🇳National Cancer Institute, Jhajjar, Haryana, India
🇮🇳PMCH (Pacific Medical College & Hospital), Udaipur, Rajasthan, India
News
No news found